LISA R MERLIN

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology BROOKLYN, NY NPI 1619954518

General Payments — all program years on this page

$4,933.17

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 81
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $753.80 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $753.8019

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
EISAI INC. $164.793
SK Life Science, Inc. $161.193
ARGENX US, INC. $158.653
Octapharma USA, Inc. $74.712
Neurocrine BioSciences, Inc. $58.452
UCB, Inc. $48.172
Acerta Pharma LLC $39.642
PFIZER INC. $26.951
Alnylam Pharmaceuticals Inc. $21.251

By program year

Program yearAmountRecords
2018 $719.948
2019 $1,426.4912
2020 $375.003
2021 $325.003
2022 $15.611
2023 $1,317.3335
2024 $753.8019

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1104477794 AstraZeneca Pharmaceuticals LP $20.28 05/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104544074 AstraZeneca Pharmaceuticals LP $19.36 05/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1110760816 Eisai Inc. $13.84 05/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1110760818 Eisai Inc. $25.95 10/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1110760820 Eisai Inc. $125.00 09/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125843907 Alnylam Pharmaceuticals Inc. $21.25 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131421229 PFIZER INC. $26.95 01/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142116198 ARGENX US, INC. $125.00 09/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142119785 ARGENX US, INC. $26.21 11/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142119787 ARGENX US, INC. $7.44 11/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142317044 Octapharma USA, Inc. $36.86 02/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142317046 Octapharma USA, Inc. $37.85 09/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143063487 UCB, Inc. $23.68 02/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143063489 UCB, Inc. $24.49 05/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150818298 Neurocrine Biosciences, Inc. $35.72 09/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150847469 Neurocrine Biosciences, Inc. $22.73 07/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154133225 SK Life Science, Inc. $15.06 01/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154133373 SK Life Science, Inc. $125.00 05/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154133377 SK Life Science, Inc. $21.13 12/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.